Mani Foroohar’s rating is based on positive interim clinical data from Neurogene’s low-dose cohort of NGN-401 in treating Rett syndrome, showing significant improvements in patients’ core clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback